|
US2856420A
(en)
|
1955-12-15 |
1958-10-14 |
Minnesota Mining & Mfg |
Perfluoro- and perfluorochlorocarboxylic acid esters of amino alcohols
|
|
US3340299A
(en)
|
1964-03-27 |
1967-09-05 |
Air Reduction |
Tetrasubstituted ethylene diamines
|
|
GB1277947A
(en)
|
1968-08-22 |
1972-06-14 |
Armour Ind Chem Co |
Compositions and method for controlling insect pests
|
|
US4491583A
(en)
|
1970-08-07 |
1985-01-01 |
Pfizer Inc. |
Interferon induction in animals by amines
|
|
US3729564A
(en)
|
1970-12-16 |
1973-04-24 |
Pfizer |
N-secondary alkyl alkanediamines and derivatives thereof as anti-inflammatory agents
|
|
JPS5122416B2
(https=)
|
1972-11-11 |
1976-07-09 |
|
|
|
JPS5718088B2
(https=)
|
1972-06-22 |
1982-04-14 |
|
|
|
DE2633615C3
(de)
|
1976-07-27 |
1981-08-13 |
Bayer Ag, 5090 Leverkusen |
Verfahren zum Färben von synthetischen Polyamid-Fasermaterialien
|
|
DE3010599A1
(de)
|
1979-03-22 |
1980-10-09 |
Continental Pharma |
Derivate von glycinamid, deren herstellung und verwendung
|
|
US4883751A
(en)
|
1986-05-28 |
1989-11-28 |
New York University |
Specific immunoassay for heparin
|
|
US5858980A
(en)
|
1990-03-30 |
1999-01-12 |
Autoimmune, Inc. |
Peptide fragments of myelin basic protein
|
|
JP2588339B2
(ja)
|
1992-06-02 |
1997-03-05 |
花王株式会社 |
新規ジアミノジエステル及びその製造法
|
|
US6197553B1
(en)
|
1994-07-15 |
2001-03-06 |
Merck & Co., Inc. |
Method for large scale plasmid purification
|
|
FR2727679B1
(fr)
|
1994-12-05 |
1997-01-03 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfection et leurs applications pharmaceutiques
|
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
ATE285477T1
(de)
|
1995-06-07 |
2005-01-15 |
Inex Pharmaceutical Corp |
Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
|
|
US5705385A
(en)
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
EP0869937A4
(en)
|
1995-07-21 |
2004-07-21 |
Promega Biosciences Inc |
AMID BASED CATIONIC LIPIDS
|
|
DE19605175A1
(de)
|
1996-02-13 |
1997-08-14 |
Sourovoi Andrej Dr |
Lipidverbindungen und deren Verwendung
|
|
JPH103643A
(ja)
|
1996-06-12 |
1998-01-06 |
Fuji Photo Film Co Ltd |
ディスク状磁気記録媒体
|
|
DE69628052T2
(de)
|
1996-10-11 |
2004-02-19 |
Infineum Holdings Bv |
Brennstoffzusammensetzungen
|
|
CA2217550A1
(en)
|
1996-10-22 |
1998-04-22 |
F. Hoffmann-La Roche Ag |
Cationic lipids for gene therapy
|
|
US6884430B1
(en)
|
1997-02-10 |
2005-04-26 |
Aventis Pharma S.A. |
Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
|
|
US5965542A
(en)
|
1997-03-18 |
1999-10-12 |
Inex Pharmaceuticals Corp. |
Use of temperature to control the size of cationic liposome/plasmid DNA complexes
|
|
US5756785A
(en)
|
1997-03-21 |
1998-05-26 |
Lambent Technologies, Inc. |
Guerbet betaines
|
|
FR2763943B1
(fr)
|
1997-05-28 |
1999-07-09 |
Rhone Poulenc Rorer Sa |
Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
|
|
US6395713B1
(en)
|
1997-07-23 |
2002-05-28 |
Ribozyme Pharmaceuticals, Inc. |
Compositions for the delivery of negatively charged molecules
|
|
CA2315695A1
(en)
|
1997-12-23 |
1999-07-08 |
Inex Pharmaceuticals Corporation |
Polyamide oligomers
|
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
US6986902B1
(en)
|
1998-04-28 |
2006-01-17 |
Inex Pharmaceuticals Corporation |
Polyanionic polymers which enhance fusogenicity
|
|
US6013813A
(en)
|
1998-06-17 |
2000-01-11 |
Hansotech Inc |
Guerbet based sorbitan esters
|
|
US6333433B1
(en)
|
1998-11-09 |
2001-12-25 |
Council Of Scientific Industrial Research |
Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkl group for intracellular delivery of biologically active molecules
|
|
US6656498B1
(en)
|
1998-11-25 |
2003-12-02 |
Vanderbilt University |
Cationic liposomes for gene transfer
|
|
US5919743A
(en)
|
1998-12-28 |
1999-07-06 |
Petroferm Inc. |
Guerbet branched quaternary compounds in personal care applications
|
|
US7112337B2
(en)
|
1999-04-23 |
2006-09-26 |
Alza Corporation |
Liposome composition for delivery of nucleic acid
|
|
US6211140B1
(en)
|
1999-07-26 |
2001-04-03 |
The Procter & Gamble Company |
Cationic charge boosting systems
|
|
ATE289630T1
(de)
|
1999-09-09 |
2005-03-15 |
Curevac Gmbh |
Transfer von mrnas unter verwendung von polykationischen verbindungen
|
|
GB9930533D0
(en)
|
1999-12-23 |
2000-02-16 |
Mitsubishi Tokyo Pharm Inc |
Nucleic acid delivery
|
|
JP2001338416A
(ja)
|
2000-05-25 |
2001-12-07 |
Sony Corp |
ディスク状磁気記録媒体
|
|
US20040142474A1
(en)
|
2000-09-14 |
2004-07-22 |
Expression Genetics, Inc. |
Novel cationic lipopolymer as a biocompatible gene delivery agent
|
|
EP1471885A4
(en)
|
2002-01-09 |
2009-04-22 |
Transave Inc |
EFFECTIVE LIPOSOM ASSORTMENT
|
|
JP4111856B2
(ja)
|
2002-04-12 |
2008-07-02 |
昭和電工株式会社 |
安定化されたアスコルビン酸誘導体
|
|
US7901708B2
(en)
|
2002-06-28 |
2011-03-08 |
Protiva Biotherapeutics, Inc. |
Liposomal apparatus and manufacturing methods
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
US6620794B1
(en)
|
2002-07-08 |
2003-09-16 |
Colonial Chemical Inc. |
Guerbet functionalized phospholipids
|
|
EP1530585A2
(en)
|
2002-08-22 |
2005-05-18 |
Cytos Biotechnology AG |
Inducible alphaviral/orip based gene expression system
|
|
ES2559828T3
(es)
|
2003-07-16 |
2016-02-16 |
Protiva Biotherapeutics Inc. |
ARN de interferencia encapsulado en lípidos
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
NZ592917A
(en)
|
2003-09-15 |
2012-12-21 |
Protiva Biotherapeutics Inc |
Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
|
|
US7811602B2
(en)
|
2004-05-17 |
2010-10-12 |
Tekmira Pharmaceuticals Corporation |
Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
|
|
US7799565B2
(en)
|
2004-06-07 |
2010-09-21 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
US9006487B2
(en)
*
|
2005-06-15 |
2015-04-14 |
Massachusetts Institute Of Technology |
Amine-containing lipids and uses thereof
|
|
US9005654B2
(en)
|
2005-07-27 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Systems and methods for manufacturing liposomes
|
|
EP3611266B1
(en)
|
2005-08-23 |
2022-11-09 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
JP4681425B2
(ja)
|
2005-11-15 |
2011-05-11 |
花王株式会社 |
毛髪弾性改善剤
|
|
DE102006035618A1
(de)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
|
EP3192788A1
(en)
|
2006-10-03 |
2017-07-19 |
Arbutus Biopharma Corporation |
Lipid containing formulations
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
WO2008109806A2
(en)
|
2007-03-08 |
2008-09-12 |
Massachusetts Institute Of Technology |
Electrostatic coating of particles for drug delivery
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
|
WO2009082607A2
(en)
|
2007-12-04 |
2009-07-02 |
Alnylam Pharmaceuticals, Inc. |
Targeting lipids
|
|
CA3252166A1
(en)
|
2008-01-02 |
2025-11-29 |
Arbutus Biopharma Corporation |
Screening method for selected amino lipid-containing compositions
|
|
US20110045473A1
(en)
|
2008-01-02 |
2011-02-24 |
De Fougerolles Antonin |
Liver screening method
|
|
EP2176408B9
(en)
|
2008-01-31 |
2015-11-11 |
Curevac GmbH |
NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
|
|
WO2009126933A2
(en)
|
2008-04-11 |
2009-10-15 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
WO2009132131A1
(en)
|
2008-04-22 |
2009-10-29 |
Alnylam Pharmaceuticals, Inc. |
Amino lipid based improved lipid formulation
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
|
WO2010048536A2
(en)
|
2008-10-23 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for preparing lipids
|
|
WO2010062322A2
(en)
|
2008-10-27 |
2010-06-03 |
Massachusetts Institute Of Technology |
Modulation of the immune response
|
|
HUE037082T2
(hu)
|
2008-11-10 |
2018-08-28 |
Arbutus Biopharma Corp |
Új lipidek és készítmények terápiás hatóanyagok szállítására
|
|
WO2010054384A1
(en)
|
2008-11-10 |
2010-05-14 |
Alnylam Pharmaceuticals, Inc. |
Lipids and compositions for the delivery of therapeutics
|
|
CN102231950A
(zh)
|
2008-11-17 |
2011-11-02 |
安龙制药公司 |
用于核酸递送系统的可释放聚合脂质
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
KR20180094137A
(ko)
|
2009-05-05 |
2018-08-22 |
알닐람 파마슈티칼스 인코포레이티드 |
지질 조성물
|
|
JP5889783B2
(ja)
|
2009-05-05 |
2016-03-22 |
テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ |
免疫細胞へオリゴヌクレオチドを送達する方法
|
|
MX342785B
(es)
|
2009-06-10 |
2016-10-12 |
Alnylam Pharmaceuticals Inc |
Formulacion mejorada de lipido.
|
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
EP4218799A1
(en)
|
2009-07-15 |
2023-08-02 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
|
WO2011036557A1
(en)
|
2009-09-22 |
2011-03-31 |
The University Of British Columbia |
Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
|
|
CA2816925C
(en)
|
2009-11-04 |
2023-01-10 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
|
EP2506879A4
(en)
|
2009-12-01 |
2014-03-19 |
Protiva Biotherapeutics Inc |
PREPARATIONS OF SNALP CONTAINING ANTIOXIDANTS
|
|
WO2011071860A2
(en)
|
2009-12-07 |
2011-06-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions for nucleic acid delivery
|
|
CA2784568A1
(en)
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Lipid particles for delivery of nucleic acids
|
|
US20130129811A1
(en)
|
2010-04-28 |
2013-05-23 |
Takeshi Kuboyama |
Cationic lipid
|
|
JP5902616B2
(ja)
|
2010-04-28 |
2016-04-13 |
協和発酵キリン株式会社 |
カチオン性脂質
|
|
US9254327B2
(en)
|
2010-05-10 |
2016-02-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2011141705A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
WO2011141703A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
|
SG186085A1
(en)
|
2010-06-03 |
2013-01-30 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the delivery of active agents
|
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
HUE047796T2
(hu)
|
2010-07-06 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
RNS bevitele több immunútvonal bekapcsolására
|
|
PL2591114T3
(pl)
|
2010-07-06 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Immunizacja dużych ssaków małymi dawkami rna
|
|
RS63817B1
(sr)
|
2010-07-06 |
2023-01-31 |
Glaxosmithkline Biologicals Sa |
Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
|
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
RS63890B1
(sr)
|
2010-08-31 |
2023-02-28 |
Glaxosmithkline Biologicals Sa |
Mali lipozomi za isporuku rnk koja kodira imunogen
|
|
PT3970742T
(pt)
|
2010-08-31 |
2022-06-27 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para entrega de arn codificador de imunogénio
|
|
ES2727583T3
(es)
|
2010-08-31 |
2019-10-17 |
Glaxosmithkline Biologicals Sa |
Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
JP2013544504A
(ja)
|
2010-10-11 |
2013-12-19 |
ノバルティス アーゲー |
抗原送達プラットフォーム
|
|
US20120136073A1
(en)
|
2010-11-15 |
2012-05-31 |
Life Technologies Corporation |
Amine-Containing Transfection Reagents and methods for making and using same
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US8691750B2
(en)
|
2011-05-17 |
2014-04-08 |
Axolabs Gmbh |
Lipids and compositions for intracellular delivery of biologically active compounds
|
|
WO2013006838A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
US11058762B2
(en)
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
EP2734531A1
(en)
|
2011-07-22 |
2014-05-28 |
Université de Strasbourg |
Phospholipid-detergent conjugates and uses thereof
|
|
WO2013016058A1
(en)
|
2011-07-22 |
2013-01-31 |
Merck Sharp & Dohme Corp. |
Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
|
|
EP3508220A1
(en)
|
2011-08-31 |
2019-07-10 |
GlaxoSmithKline Biologicals S.A. |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
US9126966B2
(en)
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
|
AU2012312260B2
(en)
|
2011-09-21 |
2017-08-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
|
EP2760477B1
(en)
|
2011-09-27 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
|
JP6294229B2
(ja)
|
2011-10-18 |
2018-03-14 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
アミン陽イオン性脂質およびその使用
|
|
KR102451116B1
(ko)
|
2011-10-27 |
2022-10-06 |
메사추세츠 인스티튜트 오브 테크놀로지 |
약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
|
|
JP2013095755A
(ja)
|
2011-11-02 |
2013-05-20 |
Kyowa Hakko Kirin Co Ltd |
カチオン性脂質
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
EP2788316B1
(en)
|
2011-12-07 |
2019-04-24 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
EP2788006B1
(en)
|
2011-12-07 |
2026-01-07 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
CN102604115B
(zh)
|
2012-02-22 |
2013-07-10 |
天津大学 |
羧甲基壳聚糖季铵盐/pamam核壳纳米粒及制备方法
|
|
SG11201405157PA
(en)
|
2012-02-24 |
2014-10-30 |
Protiva Biotherapeutics Inc |
Trialkyl cationic lipids and methods of use thereof
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
SG10201607962RA
(en)
|
2012-03-27 |
2016-11-29 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
WO2013143700A2
(en)
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules comprising a 5'top utr
|
|
RU2658490C2
(ru)
|
2012-03-27 |
2018-06-21 |
Кьюрвак Аг |
Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
|
|
WO2013148541A1
(en)
|
2012-03-27 |
2013-10-03 |
Merck Sharp & Dohme Corp. |
DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
|
|
WO2013174409A1
(en)
|
2012-05-25 |
2013-11-28 |
Curevac Gmbh |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
|
US20150140068A1
(en)
|
2012-07-06 |
2015-05-21 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
|
WO2014008334A1
(en)
|
2012-07-06 |
2014-01-09 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
EP2882706A1
(en)
|
2012-08-13 |
2015-06-17 |
Massachusetts Institute of Technology |
Amine-containing lipidoids and uses thereof
|
|
US9687448B2
(en)
|
2012-12-07 |
2017-06-27 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid lipid particle formulations
|
|
EP2943221A1
(en)
|
2013-01-10 |
2015-11-18 |
Novartis AG |
Influenza virus immunogenic compositions and uses thereof
|
|
RU2718988C2
(ru)
|
2013-02-22 |
2020-04-15 |
Куревак Аг |
Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
US20160030527A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and Methods for Treatment of Stroke
|
|
WO2014153163A1
(en)
|
2013-03-14 |
2014-09-25 |
Dicerna Pharmaceuticals, Inc. |
Process for formulating an anionic agent
|
|
WO2015024664A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Composition and vaccine for treating prostate cancer
|
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
|
BR112016001192A2
(pt)
|
2013-08-21 |
2017-08-29 |
Curevac Ag |
Vacina contra a raiva
|
|
SG11201510747RA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
|
BR112016003361A2
(pt)
|
2013-08-21 |
2017-11-21 |
Curevac Ag |
vacina do vírus sincicial respiratório (rsv)
|
|
ES2806575T3
(es)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
ARN modificado con propiedades inmunoestimuladoras disminuidas
|
|
US9593077B2
(en)
|
2013-11-18 |
2017-03-14 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
KR102399799B1
(ko)
|
2013-12-30 |
2022-05-18 |
큐어백 아게 |
인공 핵산 분자
|
|
WO2015123576A2
(en)
|
2014-02-17 |
2015-08-20 |
The Brigham And Women's Hospital, Inc. |
Targeted nanoparticle compositions and methods of their use to treat obesity
|
|
US10821175B2
(en)
|
2014-02-25 |
2020-11-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
CA2936286A1
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
US10309541B2
(en)
|
2014-05-22 |
2019-06-04 |
Flowserve S.R.L. |
Guide element for a valve actuator and actuator provided with said guide element
|
|
SMT202200502T1
(it)
|
2014-06-25 |
2023-01-13 |
Acuitas Therapeutics Inc |
Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
|
|
EP3169309B1
(en)
|
2014-07-16 |
2023-05-10 |
Novartis AG |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
JP6339884B2
(ja)
|
2014-07-17 |
2018-06-06 |
富士フイルム株式会社 |
イミダゾール化合物およびそれを含有するリポソーム
|
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
DE202015010000U1
(de)
|
2014-12-12 |
2023-07-03 |
CureVac SE |
Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
|
|
CA2962849A1
(en)
|
2014-12-16 |
2016-06-23 |
Curevac Ag |
Ebolavirus and marburgvirus vaccines
|
|
KR102580696B1
(ko)
|
2014-12-30 |
2023-09-19 |
큐어백 에스이 |
신규 인공 핵산 분자
|
|
CN104876831B
(zh)
|
2015-04-03 |
2017-05-17 |
苏州圣诺生物医药技术有限公司 |
脂质修饰精胺衍生物及利用该衍生物制备的脂质体
|
|
EP3283059B1
(en)
|
2015-04-13 |
2024-01-03 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
US20180303925A1
(en)
|
2015-04-27 |
2018-10-25 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
|
|
KR20180004820A
(ko)
|
2015-05-15 |
2018-01-12 |
큐어백 아게 |
적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
|
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
|
LT3313829T
(lt)
|
2015-06-29 |
2024-08-12 |
Acuitas Therapeutics Inc. |
Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
|
|
WO2017021546A1
(en)
|
2015-08-05 |
2017-02-09 |
Curevac Ag |
Epidermal mrna vaccine
|
|
DK3332019T3
(da)
|
2015-08-07 |
2020-02-17 |
Curevac Ag |
Fremgangsmåde til in vivo-produktionen af rna i en værtscelle
|
|
CA2992801A1
(en)
|
2015-08-28 |
2017-03-09 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
WO2017048770A1
(en)
|
2015-09-15 |
2017-03-23 |
Regulus Therapeutics, Inc. |
Systems, compositions, and methods for formulating nucleic acid compositions
|
|
EP4286012A3
(en)
|
2015-09-17 |
2024-05-29 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
TW201729835A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道病毒疫苗
|
|
US20180289792A1
(en)
|
2015-10-22 |
2018-10-11 |
ModernaTX. Inc. |
Sexually transmitted disease vaccines
|
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP3374504B1
(en)
|
2015-11-09 |
2025-03-19 |
CureVac SE |
Optimized nucleic acid molecules
|
|
US11413346B2
(en)
|
2015-11-09 |
2022-08-16 |
Curevac Ag |
Rotavirus vaccines
|
|
HUE057877T2
(hu)
|
2015-12-22 |
2022-06-28 |
Modernatx Inc |
Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
|
|
EP3397613A1
(en)
|
2015-12-30 |
2018-11-07 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US11723967B2
(en)
|
2016-02-17 |
2023-08-15 |
CureVac SE |
Zika virus vaccine
|
|
US20170266292A1
(en)
|
2016-03-21 |
2017-09-21 |
The Research Foundation For The State University Of New York |
Lipidic compound-telodendrimer hybrid nanoparticles and methods of making and uses thereof
|
|
TWI773666B
(zh)
|
2016-03-30 |
2022-08-11 |
美商英特利亞醫療公司 |
Crispr/cas 組分之脂質奈米粒子調配物
|
|
EP3777881A1
(en)
|
2016-04-22 |
2021-02-17 |
CureVac AG |
Rna encoding a tumor antigen
|
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
|
EP3454835B1
(en)
|
2016-05-09 |
2021-03-31 |
Astrazeneca AB |
Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
BR112019008481A2
(pt)
|
2016-10-26 |
2020-03-03 |
Curevac Ag |
Vacinas de mrna de nanopartículas lipídicas
|
|
WO2018081638A1
(en)
|
2016-10-27 |
2018-05-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
EP3551169A4
(en)
|
2016-12-09 |
2020-09-09 |
Sangamo Therapeutics, Inc. |
TARGET-SPECIFIC NUCLEASES ADMINISTRATION
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
*
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2019027999A1
(en)
*
|
2017-07-31 |
2019-02-07 |
Ohio State Innovation Foundation |
BIOMIMETIC NANOMATERIALS AND USES THEREOF
|
|
CA3073020A1
(en)
*
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
EP3668834B1
(en)
|
2017-08-17 |
2024-10-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
JP7543259B2
(ja)
|
2018-10-18 |
2024-09-02 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
MY202837A
(en)
|
2019-01-11 |
2024-05-24 |
Acuitas Therapeutics Inc |
Lipids for lipid nanoparticle delivery of active agents
|
|
US20230097090A1
(en)
|
2019-08-14 |
2023-03-30 |
Acuitas Therapeutics, Inc. |
Improved lipid nanoparticles for delivery of nucleic acids
|
|
WO2022016070A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|